Last updated: October 15, 2026
Quinapril hydrochloride/hydrochlorothiazide is a mature fixed-dose antihypertensive combination with minimal remaining exclusivity value. The branded product, Accuretic, lost meaningful commercial protection years ago, faced generic substitution, and was later affected by nitrosamine-related recalls. The current market is a low-price, low-growth generic segment with limited manufacturer investment and no biosimilar exposure.
What is quinapril hydrochloride and hydrochlorothiazide used for?
Quinapril hydrochloride/hydrochlorothiazide combines an angiotensin-converting enzyme inhibitor with a thiazide diuretic.
| Component |
Pharmacologic role |
| Quinapril hydrochloride |
ACE inhibitor that reduces angiotensin II formation and aldosterone activity |
| Hydrochlorothiazide |
Thiazide diuretic that increases sodium and water excretion |
| Combination |
Blood-pressure reduction through complementary mechanisms |
The combination was marketed for hypertension in patients who required more than one antihypertensive agent. The branded product was sold as Accuretic in tablet strengths including 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg, although product availability has changed substantially over time.
Quinapril is converted to quinaprilat, its active metabolite. Hydrochlorothiazide remains one of the most widely used diuretics in hypertension, but fixed-dose products containing quinapril have been displaced by combinations involving lisinopril, losartan, valsartan, amlodipine, and other agents.
What is the FDA regulatory status of quinapril hydrochloride/hydrochlorothiazide?
The product has an established FDA approval history, but its commercial status is no longer comparable with a recently approved branded medicine.
Pfizer’s Accuretic product was subject to voluntary recalls after detection of N-nitroso-quinapril, a nitrosamine impurity. FDA communications in 2022 reported recalls of several lots of quinapril and hydrochlorothiazide tablets because of elevated nitrosamine levels.[1]
The regulatory consequences were commercial rather than a new exclusivity event:
- The active ingredients remained approved for antihypertensive use.
- Recalled lots were removed from distribution.
- Supply became less reliable.
- Prescribers and pharmacies shifted toward alternative ACE inhibitor/thiazide combinations and other antihypertensive classes.
- Manufacturers faced additional testing, process-control, and supply-chain obligations.
FDA’s Orange Book distinguishes between approved applications, marketed status, and patent or exclusivity listings. A product may retain an approved application while having little or no commercial supply. That distinction is important for quinapril/hydrochlorothiazide because regulatory approval does not establish material market value.
What patents protect quinapril hydrochloride and hydrochlorothiazide?
The core composition and use patents for quinapril and the fixed-dose combination are long expired or have no practical effect on current generic entry.
Quinapril originated from the ACE inhibitor patent estate associated with Warner-Lambert and related predecessor organizations. The relevant compound and pharmaceutical-composition patents were filed in the 1970s and 1980s. Any ordinary U.S. patent term for those early filings ended years ago, subject to applicable patent-term adjustments and transitional rules.
The commercial patent position can be summarized as follows:
| Protection category |
Current commercial relevance |
| Quinapril compound patents |
Expired |
| Hydrochlorothiazide compound patents |
Expired |
| Fixed-dose composition patents |
Expired or commercially exhausted |
| Basic hypertension method patents |
Expired |
| Product-specific formulation patents |
No known meaningful barrier to standard generic tablets |
| Manufacturing-process patents |
Potentially relevant to individual suppliers, but not a general market barrier |
| Regulatory exclusivity |
Expired |
A complete current patent opinion would require a live review of FDA Orange Book records, USPTO Patent Center, terminal disclaimers, continuations, and any jurisdiction-specific litigation filings. The market conclusion is nevertheless clear: patent protection does not prevent generic competition for quinapril hydrochloride/hydrochlorothiazide.
When did quinapril hydrochloride/hydrochlorothiazide lose exclusivity?
The product lost meaningful market exclusivity in the early generic era, well before the 2020s.
Quinapril’s branded product, Accupril, and the combination product Accuretic were introduced decades ago. Generic quinapril and quinapril/hydrochlorothiazide products subsequently entered the U.S. market after expiration of the principal patents and regulatory exclusivities.
The relevant commercial timeline is:
| Period |
Market event |
| 1980s |
Quinapril and combination-product development and patenting |
| Late 1980s to early 1990s |
U.S. branded commercialization of Accupril and Accuretic |
| Early 2000s and earlier |
Principal compound and formulation exclusivity expired |
| 2000s-2010s |
Generic substitution expanded and prices declined |
| 2020-2022 |
Nitrosamine testing and supply concerns affected quinapril products |
| 2022 onward |
Recalls and reduced commercial availability weakened the branded franchise |
The product therefore has no meaningful “patent cliff” remaining. Its commercial decline occurred through gradual generic erosion, therapeutic substitution, and supply disruption rather than through a single recent loss-of-exclusivity event.
How many patents cover quinapril hydrochloride/hydrochlorothiazide today?
No active patent portfolio appears to create a material, product-wide entry barrier for standard quinapril/hydrochlorothiazide tablets in the United States.
The practical patent count is more relevant than the historical number of filings:
- Historical quinapril compound patents: multiple.
- Historical combination and formulation filings: multiple.
- Active blocking patents for the basic fixed-dose tablet: no material barrier identified.
- Potential process patents: supplier-specific and unlikely to prevent alternative generic manufacture.
- Method-of-use patents: no commercially significant remaining exclusivity identified for the established hypertension indication.
A patent may remain listed or appear in a historical prosecution record without having meaningful blocking power. Expired patents, non-asserted claims, unenforceable claims, and claims that do not cover a generic’s process do not materially alter entry economics.
Are there Paragraph IV challenges for quinapril hydrochloride/hydrochlorothiazide?
Paragraph IV litigation is not a current central market issue because the principal product patents expired long ago.
A generic applicant may historically have filed an ANDA with a Paragraph IV certification against listed patents. That pathway would have been relevant during the original generic-entry period. It is not an important present-day driver of the market because:
- The principal patents are expired.
- The branded product has limited commercial value.
- Generic suppliers can rely on non-infringement, invalidity, or expired-patent positions.
- The revenue available to support high-cost patent litigation is small.
No active, commercially significant Paragraph IV campaign is associated with the current quinapril/hydrochlorothiazide market based on the publicly established product history.
What formulations are protected by quinapril/hydrochlorothiazide patents?
The relevant commercial formulation is an immediate-release oral tablet containing quinapril hydrochloride and hydrochlorothiazide. The historical product strengths included:
- 10 mg quinapril hydrochloride/12.5 mg hydrochlorothiazide
- 20 mg quinapril hydrochloride/12.5 mg hydrochlorothiazide
- 20 mg quinapril hydrochloride/25 mg hydrochlorothiazide
No extended-release, transdermal, injectable, implantable, or biologic formulation has become commercially important for this combination.
Historical formulation protection would generally have addressed tablet composition, dosage strength, manufacturing, stability, or combination use. Those claims do not provide current exclusivity against ordinary generic tablets.
What is the Orange Book status of Accuretic?
Accuretic’s Orange Book relevance is limited by its age, generic competition, and uncertain marketed status.
The Orange Book should be analyzed across four separate questions:
- Is the reference listed drug approved?
- Is it currently marketed?
- Are patents listed against the application?
- Does any listed patent remain unexpired?
For quinapril/hydrochlorothiazide, the fourth question controls commercial risk. Historic listings cannot block entry once the listed patents expire. A product may appear in FDA records even if the branded medicine is no longer actively promoted or broadly supplied.
The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations remains the controlling source for current application, patent, exclusivity, and therapeutic-equivalence information.[2]
What is the financial trajectory of quinapril hydrochloride/hydrochlorothiazide?
The product’s financial trajectory is one of long-term erosion followed by commoditization and supply-related contraction.
Branded revenue
Standalone Accuretic revenue is not generally reported as a separate material line item in public company filings. Pfizer’s financial reports aggregate products into broader portfolios, therapeutic categories, or geographic segments. The product’s age and generic competition indicate that its contribution was immaterial relative to Pfizer’s major branded products.
The financial pattern was therefore:
- High value during the protected branded period.
- Sharp decline after generic entry.
- Further erosion as physicians adopted newer combinations.
- Lower prices under pharmacy substitution.
- Additional volume loss following recalls and supply interruptions.
- No credible path to restored branded pricing without a new formulation, indication, or supply advantage.
Generic revenue
Generic quinapril/hydrochlorothiazide revenue is distributed across multiple manufacturers and is not normally disclosed by product in annual reports. Pricing pressure is high because:
- The active ingredients are old and widely available.
- The formulation is technically simple.
- Several substitute combinations exist.
- Pharmacy benefit managers favor low-cost suppliers.
- Market demand is stable but not expanding rapidly.
- Recalls can shift volume between suppliers without increasing total market value.
The segment can generate modest cash flow for a low-cost manufacturer with reliable supply. It does not offer the margin profile associated with a protected specialty product.
Which companies compete in the quinapril/hydrochlorothiazide market?
Competition has historically included the branded originator and multiple generic manufacturers. Generic availability has varied by strength, dosage form, manufacturing site, and period.
The competitive set includes manufacturers that have marketed or supplied generic quinapril and hydrochlorothiazide products through ANDAs, including large generic companies and contract-manufacturing networks. Public availability has been affected by recalls and discontinuations, so a historical label or ANDA does not establish current commercial supply.
The more important competitive products are not necessarily quinapril-based. They include:
| Combination |
Competitive position |
| Lisinopril/hydrochlorothiazide |
Stronger generic familiarity and broad prescribing base |
| Enalapril/hydrochlorothiazide |
Established ACE inhibitor alternative |
| Losartan/hydrochlorothiazide |
Major ARB-based substitute |
| Valsartan/hydrochlorothiazide |
Branded and generic ARB alternative |
| Amlodipine plus an ACE inhibitor or ARB |
Common multidrug regimen |
| Single-agent ACE inhibitors or ARBs |
Often preferred for titration flexibility |
Quinapril’s use is also constrained by the availability of lisinopril, which has a simpler dosing profile, extensive clinical familiarity, and deep generic penetration.
How does quinapril/hydrochlorothiazide compare with lisinopril/hydrochlorothiazide?
Lisinopril/hydrochlorothiazide has the stronger current commercial position.
| Factor |
Quinapril/hydrochlorothiazide |
Lisinopril/hydrochlorothiazide |
| Patent status |
Expired |
Expired |
| Generic competition |
Mature but limited and supply-sensitive |
Broad and established |
| Prescriber familiarity |
Lower |
Higher |
| Current commercial momentum |
Weak |
More durable |
| Nitrosamine-related exposure |
Quinapril-specific supply concerns affected the product |
Separate product-specific risks |
| Reimbursement position |
Low-price generic |
Low-price generic |
| Growth outlook |
Declining or flat |
Stable generic demand |
The combination’s principal weakness is not patent exposure. It is therapeutic substitution. Once prescribers can obtain a familiar alternative at similar or lower cost, quinapril/hydrochlorothiazide has limited ability to recover share.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are operational rather than patent-based.
A supplier must control:
- Nitrosamine formation and carryover.
- Quinapril stability and degradation.
- Blend uniformity for low-dose hydrochlorothiazide.
- Tablet dissolution and content uniformity.
- Raw-material quality.
- FDA current good manufacturing practice compliance.
- Reliable supply of active pharmaceutical ingredients.
- Registration and inspection status across manufacturing sites.
The nitrosamine issue increased the importance of analytical testing and process controls. It did not create a durable patent moat. A manufacturer with validated processes and clean regulatory history can compete, but the market price may not justify extensive remediation or capacity expansion.
What generic launch scenarios exist?
The most likely commercial scenarios are:
Continued low-volume generic supply
One or more manufacturers maintain limited supply of selected strengths. Pricing remains low, and distribution is concentrated among wholesalers and pharmacy networks.
Product discontinuation
If testing, remediation, or manufacturing costs exceed expected revenue, suppliers may discontinue one or more strengths. This risk is higher for low-volume strengths and products with unstable procurement economics.
Therapeutic substitution
Patients are moved to lisinopril/hydrochlorothiazide, losartan/hydrochlorothiazide, or separate-component therapy. This is the most commercially durable substitute scenario.
Re-entry by a generic manufacturer
A supplier could re-enter after resolving manufacturing or impurity issues. Re-entry would likely restore availability rather than generate pricing power because the market remains off-patent.
What patent litigation and settlement agreements affect the product?
No current high-value patent litigation or settlement agreement appears to control market entry for quinapril/hydrochlorothiazide.
Historical generic-entry disputes may have involved certifications against expired or subsequently expired patents. Those disputes have little present value unless they established a continuing contractual restriction, which is not a typical feature of a fully commoditized antihypertensive product.
The absence of current litigation is itself commercially relevant. It means that the principal risks are regulatory, supply-related, and demand-related rather than legal.
Is there biosimilar risk for quinapril/hydrochlorothiazide?
There is no biosimilar risk.
Quinapril/hydrochlorothiazide is a chemically synthesized small-molecule tablet. Competitors use the ANDA generic pathway, not the biosimilar pathway under the Public Health Service Act.
The relevant competition risks are:
- ANDA approvals
- Generic price erosion
- Therapeutic substitution
- Manufacturing recalls
- API supply disruption
- Pharmacy-channel delisting
What is the geographic coverage of the patent estate?
The historical patent estate would have included U.S. and international filings covering quinapril, pharmaceutical compositions, processes, and combination products. Those rights are largely expired in major markets.
Current geographic commercial value is more dependent on regulatory status and supplier availability than patent coverage:
| Region |
Current IP relevance |
Commercial condition |
| United States |
Low |
Generic and supply-sensitive |
| European Union |
Low |
Generic ACE inhibitor/thiazide competition |
| Japan |
Low |
Mature antihypertensive market |
| Emerging markets |
Low to moderate |
Regulatory registration and procurement determine access |
| Low-income markets |
Low |
Price and supply dominate |
What is the investment outlook for quinapril/hydrochlorothiazide?
The product has low strategic value as a standalone pharmaceutical asset.
An acquisition or licensing opportunity would be defensible only where the buyer has:
- Existing generic manufacturing capacity.
- A validated nitrosamine-control program.
- Distribution access.
- Low-cost API sourcing.
- A portfolio strategy based on several related antihypertensive products.
A standalone acquisition based on patent value is unattractive because exclusivity has expired. A manufacturing or distribution transaction could still have value if it consolidates supply, resolves shortages, or improves utilization of an existing plant.
Key Takeaways
- Quinapril hydrochloride/hydrochlorothiazide is a mature, off-patent antihypertensive combination.
- Accuretic has no meaningful remaining exclusivity-based pricing power.
- Principal compound, formulation, and method-of-use protections are expired or commercially exhausted.
- Paragraph IV litigation is not a current market driver.
- The product has no biosimilar exposure because it is a small-molecule tablet.
- Nitrosamine recalls weakened availability and increased manufacturing costs.
- Lisinopril/hydrochlorothiazide and losartan/hydrochlorothiazide are stronger commercial substitutes.
- Product-specific revenue is not separately disclosed at a level that supports a reliable standalone valuation.
- Future value depends on low-cost, compliant supply rather than patents.
- Generic discontinuation or therapeutic substitution is more likely than a branded-market recovery.
FAQs About Quinapril Hydrochloride and Hydrochlorothiazide
Is Accuretic still available in the United States?
Availability has been affected by recalls, discontinuations, and generic supply conditions. FDA approval status and actual commercial availability are separate questions.
Did quinapril/hydrochlorothiazide lose exclusivity because of a recent patent expiration?
No. The product’s meaningful exclusivity ended years ago. Recent commercial disruption was linked primarily to generic erosion and nitrosamine-related recalls.
Can a generic manufacturer obtain new exclusivity for quinapril/hydrochlorothiazide?
A standard ANDA does not create new clinical exclusivity. Limited regulatory incentives could apply in specific circumstances, but they would not restore the product’s historical branded economics.
Is hydrochlorothiazide itself responsible for the product’s commercial decline?
No. Hydrochlorothiazide remains widely used. The decline reflects the specific quinapril combination, therapeutic substitution, generic pricing, and supply concerns.
Would a new quinapril/hydrochlorothiazide formulation have patent value?
A genuinely differentiated formulation could support new patent filings if it satisfied novelty and non-obviousness requirements. The existing immediate-release tablet has little remaining patent value, and a new formulation would face a low-price generic market.
References
-
U.S. Food and Drug Administration. (2022). Pfizer announces voluntary recall of quinapril and quinapril/hydrochlorothiazide tablets due to elevated levels of a nitrosamine impurity. FDA Drug Safety Communications and recall notices.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Nitrosamine impurity guidance for industry: Control of nitrosamine impurities in human drugs. https://www.fda.gov/drugs/drug-safety-and-availability
-
Pfizer Inc. (2023). Annual report and Form 10-K. New York, NY: Pfizer Inc.
-
DailyMed. (2024). Quinapril hydrochloride and hydrochlorothiazide tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/
